Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796779 | 0.85 | CYP4F2 (0.45) | CYP4F2CYP4A11SMN1; SMN2NLRP3PPARG | |
| SCHEMBL5591170 | 0.82 | CASP1 (0.55) | CYP4F2CYP4A11SMN1; SMN2NLRP3PPARG | |
| SCHEMBL2512047 | 0.78 | CYP3A4 (0.49) | ALDH1A1CYP4F2CYP4A11SMN1; SMN2PPARG | |
| SCHEMBL6873521 | 0.78 | ALDH1A1 (0.51) | ALDH1A1CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL23805673 | 0.76 | ALDH1A1 (0.43) | ALDH1A1HSD17B10CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL10909401 | 0.76 | TSHR (0.45) | ALDH1A1HSD17B10NLRP3 | |
| SCHEMBL1645936 | 0.76 | ALDH1A1 (0.49) | ALDH1A1HSD17B10CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL1646939 | 0.76 | ALDH1A1 (0.49) | ALDH1A1HSD17B10CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL2857703 | 0.76 | AOC3 (0.41) | ALDH1A1HSD17B10SMN1; SMN2PPARGCASP1 | |
| SCHEMBL6074907 | 0.74 | ALDH1A1 (0.54) | ALDH1A1HSD17B10SMN1; SMN2CASP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399448-B1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1399448-A1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6686352-B2 | USEFUL AS COGNITIVE ENHANCER OR FOR THERAPY OF COGNITIVE DISORDERS LIKE ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094834-A1 | IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | GALR1, GALR2, ADRA1A | ALDH1A1 444/4885HSD17B10 1404/4885CYP4F2 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.